These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 20153030)

  • 1. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
    Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
    J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis.
    Bowen T; Greenbaum J; Charbonneau Y; Hebert J; Filderman R; Sussman G; Del Carpio J; Gold M; Keith P; Moote W; Cecchetto S; Cecchetto O; Sharp D; Broutin O; André C
    Ann Allergy Asthma Immunol; 2004 Nov; 93(5):425-30. PubMed ID: 15562880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study.
    Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C
    Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.
    Tulic MK; Fiset PO; Christodoulopoulos P; Vaillancourt P; Desrosiers M; Lavigne F; Eiden J; Hamid Q
    J Allergy Clin Immunol; 2004 Feb; 113(2):235-41. PubMed ID: 14767435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis.
    Nayak AS; Atiee GJ; Dige E; Maloney J; Nolte H
    Allergy Asthma Proc; 2012; 33(5):404-10. PubMed ID: 23026182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study.
    Vervloet D; Birnbaum J; Laurent P; Hugues B; Fardeau MF; Massabie-Bouchat YP; Aferiat-Derome A; André C
    Int Arch Allergy Immunol; 2007; 142(3):239-46. PubMed ID: 17114889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis.
    Creticos PS; Esch RE; Couroux P; Gentile D; D'Angelo P; Whitlow B; Alexander M; Coyne TC
    J Allergy Clin Immunol; 2014 Mar; 133(3):751-8. PubMed ID: 24332263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults.
    Creticos PS; Maloney J; Bernstein DI; Casale T; Kaur A; Fisher R; Liu N; Murphy K; Nékám K; Nolte H
    J Allergy Clin Immunol; 2013 May; 131(5):1342-9.e6. PubMed ID: 23622121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ; Antvelink JB; Luwema RA
    Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
    Panzner P; Petrás M; Sýkora T; Lesná I
    Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.
    Nolte H; Hébert J; Berman G; Gawchik S; White M; Kaur A; Liu N; Lumry W; Maloney J
    Ann Allergy Asthma Immunol; 2013 Jun; 110(6):450-456.e4. PubMed ID: 23706715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
    Kleine-Tebbe J; Ribel M; Herold DA
    Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.